Biogen Pharmachem Industries (531752) Q1 25/26 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2025, at the meeting held on July 23, 2025.

• Statutory auditors conducted a limited review and found no material misstatements in the financial statements.

Financial highlights

• Revenue from operations for Q1 FY26 was ₹154.28 lakhs, up from ₹135.23 lakhs in the previous quarter and a loss of ₹9.09 lakhs in Q1 FY25.

• Net profit after tax for Q1 FY26 stood at ₹134.48 lakhs, compared to ₹117.78 lakhs in the previous quarter and a net loss of ₹15.83 lakhs in Q1 FY25.

• Total expenses for Q1 FY26 were ₹19.80 lakhs, up from ₹17.45 lakhs in the previous quarter.

• Basic and diluted EPS for Q1 FY26 was ₹0.01, compared to ₹0.02 in the previous quarter and negative in Q1 FY25.

• Paid-up equity share capital increased to ₹9,026.03 lakhs as of June 30, 2025.

Key financial ratios and metrics

• Gross margin improved significantly year-over-year, with a strong swing from negative to positive net profit.

• Earnings per share turned positive year-over-year, reflecting improved profitability.